key: cord-0867647-dl45plby authors: Abrams, Elissa M.; Greenhawt, Matthew title: Special Article: Risk Communication During COVID-19 date: 2020-04-15 journal: J Allergy Clin Immunol Pract DOI: 10.1016/j.jaip.2020.04.012 sha: b6a191193fd7516c043be730db10a288a5808006 doc_id: 867647 cord_uid: dl45plby Abstract: During the unprecedented times caused by the novel coronavirus COVID-19, there is rapidly evolving information and guidance. However, a focus must also be on proper and effective risk communication. This is especially the case during pandemics that have high rates of infection, significant morbidity, lack of therapeutic measures, and rapid increases in cases, all of which apply to the current COVID-19 pandemic. A consequence of poor risk communication and heightened risk perception is hoarding behavior, which can lead to lack of medications and personal protective equipment. One potential way to ensure appropriate risk communication is utilizing social media channels, and ensuring an ongoing consistent media presence. Another important step is to include all stakeholders including members of the allergy community in broader public health messaging. As we continue to face unprecedented times in the allergy community, an understanding and appreciation of risk communication will be essential as we communicate with, and inform, our patients, and our colleagues, moving forward. Metrics and Evaluation (IHME); Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); 23 World Health Organization (WHO) 24 25 Keywords: COVID-19, SARS-CoV-2, risk communication, health policy, pandemic planning 26 27 Conflicts of interest: Elissa Abrams is a collaborator with the Institute for Health Metrics and 28 Evaluation, is on the National Advisory Board for Food Allergy Canada, and is on the National 29 Food Allergy Action Plan Action Steering Team for Food Allergy Canada. Matthew Greenhawt is 30 supported by grant #5K08HS024599-02 from the Agency for Healthcare Research and Quality; is 31 an expert panel and coordinating committee member of the NIAID-sponsored Guidelines for 32 Peanut Allergy Prevention; has served as a consultant for the Canadian Transportation Agency, 33 Thermo Fisher, Intrommune, and Aimmune Therapeutics; is a member of physician/medical 34 advisory boards for Aimmune Therapeutics, DBV Technologies, Sanofi/Genzyme, Genentech, 35 Nutricia, Kaleo Pharmaceutical, Nestle, Acquestive, Allergy Therapeutics, Allergenis, Aravax, and 36 Monsanto; is a member of the scientific advisory council for the National Peanut Board; has 37 received honorarium for lectures from Thermo Fisher, Aimmune Therapeutics, DBV 38 Technologies, Before Brands, multiple state allergy societies, the American College of Allergy 39 Asthma and Immunology, the European Academy of Allergy and Clinical Immunology; is an 40 associate editor for the Annals of Allergy, Asthma, and Immunology; and is a member of the 41 Joint Taskforce on Allergy Practice Parameters 42 43 44 Abstract: 45 During the unprecedented times caused by the novel coronavirus COVID-19, there is rapidly 46 evolving information and guidance. However, a focus must also be on proper and effective risk 47 communication. This is especially the case during pandemics that have high rates of infection, 48 significant morbidity, lack of therapeutic measures, and rapid increases in cases, all of which 49 apply to the current COVID-19 pandemic. A consequence of poor risk communication and 50 heightened risk perception is hoarding behavior, which can lead to lack of medications and 51 personal protective equipment. One potential way to ensure appropriate risk communication is 52 utilizing social media channels, and ensuring an ongoing consistent media presence. Another 53 important step is to include all stakeholders including members of the allergy community in 54 broader public health messaging. As we continue to face unprecedented times in the allergy 55 community, an understanding and appreciation of risk communication will be essential as we 56 communicate with, and inform, our patients, and our colleagues, moving forward. threats to their health, economic or social well-being."(9) There are two broad risk models that 79 are commonly used . The first is the realist approach, whereby risk is seen to be objective and 80 independent of social context. The second is the social constructionist approach whereby risk is 81 seen to be interrelated with sociocultural context.(10) It is increasingly recognized that society, 82 communities, and our patients view risk from a social constructionist approach.(10) 83 The importance of risk management and effective risk communication cannot be 84 overstated. At the 20 th anniversary of the Chernobyl nuclear accident, the United Nations 85 released a 600-page report incorporating the works of hundreds of health experts, finding that 86 the mental health impact of Chernobyl was "the largest public health problem created by the 87 accident," attributing that profound impact to the "lack of accurate information," or improper risk communication. (11,12) As a reporter poignantly stated in response to the Fukushima 89 nuclear crisis, "risk management in a crisis has to include not just the threat itself but also how 90 people perceive and respond to the threat...The risk from how people perceive risk, is as real as 91 the physical danger itself…Far too little respect has been paid to the risk caused by the way 92 people perceive and respond to risk"(13) 93 There are aspects to pandemics that can heighten risk perception, so-called "dread (Table 1) . As we continue to face unprecedented times in 168 the allergy community, an understanding and appreciation of risk communication will be 169 essential as we communicate with, and inform, our patients, and our colleagues, moving 170 forward. 171 There is no evidence that asthma predisposes to COVID-19 but it is a theoretical risk factor for morbidity Remain on current asthma medications Avoid nebulization as it can increase viral transmission Oral corticosteroids can be used if required for asthma exacerbations Allergic rhinitis Allergic rhinitis can be differentiated from COVID-19 due to absence of fever and myalgias Service reduction in rhinitis management is strongly recommended Immunotherapy should not be initiated during COVID-19 with rare exceptions Food allergy Follow current food allergy management plan Emergency care after using epinephrine autoinjectors should be avoided unless symptoms do not improve Immunotherapy initiation and up-dosing should be deferred With rare exceptions oral challenges should be deferred With rare exceptions follow up visits should be deferred or held virtually The SARS-CoV-2 outbreak: what we know Johns Hopkins Coronavirus Resource Center -shortage-of-personal-protective-equipment-endangering-health-workers-224 worldwide 225 19. Time Magazine:There Aren't Enough Medical Masks to Fight Coronavirus. Here's Why It's 226 Not Going to Get Better Anytime Soon The Perception of Risk Public perceptions 237 of expert disagreement: Bias and incompetence or a complex and random world? Public 238 Underst Sci Lay Americans' views of why scientists disagree with each 240 other Why public opinion changes: the implications for health and health 242 policy. J Health Polit Policy Law Clinical review: SARS -lessons in disaster 244 management The Fukushima nuclear crisis reemphasizes the need for improved risk 246 communication and better use of social media Social Media Engagement and Public Health 248 Communication: Implications for Public Health Organizations Being Truly "Social 251 Social media and disasters: a functional framework for social media use in disaster 252 planning, response, and research Challenges to Transforming Unconventional Social Media Data into 254 ACAAI: COVID-19 and asthma: What you need to know moving forward Time Magazine: I've Seen Wars and Epidemics Unfold Immunocompromised Partner, the Coronavirus Makes Me Truly Scared AAAAI: Messages from the COVID-19 Response Task Force Sandman PM. Responding to community outrage: Strategies for effective risk 267 communication to-one-per-customer-as-australia-combats-coronavirus-hoarding 215